Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BigBearai Holdings Inc (BBAI) vs GSK plc (GSK) Price & Performance

BigBearai Holdings IncTrade

Price performance (Past 24H)

Key statistics

BigBearai Holdings Inc vs GSK plc — how do they compare? BigBearai Holdings Inc trades at $3.25 (market cap $1.60B), while GSK plc trades at $50.29 (market cap $102.60B). The key difference: GSK plc is far larger — about 64.1× BigBearai Holdings Inc's market cap, and GSK plc pays a 3.57% dividend while BigBearai Holdings Inc pays none. Which is the better fit depends on your goals.

BBAIGSK
Market Cap
$1.60B$102.60B
Sector
TechnologyHealth
52-Week High
$8.91$61.18
52-Week Low
$2.61$38.22
Enterprise Value
$1.30B$123.04B
Dividend Yield
3.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BigBearai Holdings Inc

BigBear.ai (BBAI) trades at $3.32, up 2.79% with a bullish technical signal. The company reported Q2 2026 revenue growth of 13% but missed EPS expectations. Despite negative profitability metrics (-65.2% net margin), the stock shows institutional interest with 75% analyst hold ratings. Recent news highlights defense contract wins and generative AI platform expansion for Department of War missions.

Outlook remains cautious due to persistent losses and revenue headwinds, though backlog growth and government contracts provide stability. Investment opportunity exists in AI defense specialization, but risks include execution challenges and competitive pressure. The stock requires careful monitoring of profitability improvements and contract execution.

GSK plc

GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.

GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BigBearai Holdings Inc

BigBearai Holdings Inc is a specialized provider of AI-driven decision intelligence solutions, primarily serving the U.S. defense, intelligence, and national security communities. It operationalizes complex data into actionable insights through its core modules—Observe, Orient, and Dominate—to support mission-critical operations and logistics.

Read more on BBAI

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Read more on GSK